ReWalk tech to help stroke, MS victims get moving

ReWalk tech to help stroke, MS victims get moving

Israeli-developed exoskeleton technology will be applied to help millions who can’t walk by themselves but are not paralyzed

Prime Minister Benjamin Netanyahu (left) and US President Barack Obama look on as disabled IDF veteran Radi Kaiuf demonstrates the ReWalk exoskeleton system. Kaiuf, who was formerly nearly fully paralyzed, completed the Israel Marathon in 2012 using the system (Kobi Gideon / GPO /FLASH90)
Prime Minister Benjamin Netanyahu (left) and US President Barack Obama look on as disabled IDF veteran Radi Kaiuf demonstrates the ReWalk exoskeleton system. Kaiuf, who was formerly nearly fully paralyzed, completed the Israel Marathon in 2012 using the system (Kobi Gideon / GPO /FLASH90)

The ReWalk system has done wonders for quadriplegics, providing them with a method of being able to walk again – or even run a marathon, as several paralyzed individuals have done while wearing the ReWalk exoskeleton suit. Now, a version of the system will be used to help a much larger cohort – individuals who have difficulty moving about due to stroke, multiple sclerosis (MS), old age, or other reasons

“There is a great need in the health care system for lightweight, lower-cost wearable exoskeleton designs to support stroke patients, individuals diagnosed with multiple sclerosis and senior citizens who require mechanical mobility assistance,” said Larry Jasinski, CEO of ReWalk. “This collaboration will help create the next generation of exoskeleton systems, making life-changing technology available to millions of consumers across a host of patient populations.”

ReWalk allows paraplegics to walk, almost the same as an able-bodied person. A forward tilt of the upper body triggers the first step and gets the system going. There are several other exoskeleton systems in development, by ReWalk is the first to receive FDA approval.

The system has been extensively studied and tested in Israel, the US, and Europe, and is in use by people around the world. In addition to providing wearers with the ability to stand and walk independently, clinical studies show that using the ReWalk provides significant mental health benefits as well, with users having a much more positive self-image as they gain independence and control over their movements, according to experts who have studied the system.

While it solves a much-needed problem, the market is limited; out of about 250,000 Americans with spinal cord injury, about half would be able to use the ReWalk exoskeleton, assuming their insurance could pay for it and they did not have other conditions preventing them from being active.

But the technology developed by Yokne’am-based ReWalk can do more than help quadriplegics walk; it can make it easier for millions who are mobility-limited to get around without the wheelchairs, walkers, and other apparatus they currently require. ReWalk has been working with Harvard University’s Wyss Institute for Biologically Inspired Engineering to develop ReWalk-based systems for individuals who have lower limb disabilities, but are not necessarily paralyzed. Last week, the company announced that the Harvard organization was licensing ReWalk’s technology to develop such systems.

Described as “soft suit exoskeleton technology,” the system uses fabric-based designs that attach to the legs and feet to transmit power to key joints of the legs with cable technologies, powered with software and mechanics that are similar to the technologies used in the ReWalk system. The system is a lot cheaper than a ReWalk exoskeleton, which provides more assistance and technology than many partially disabled people need.

Initial pilot studies with stroke patients run at Wyss, in collaboration with faculty and researchers from Boston University, have demonstrated the efficacy of soft suit exoskeleton technology. ReWalk will work in concert with the Wyss Institute on the continued development of lightweight designs to complete clinical studies, pursue regulatory approvals and commercialize the systems on a global scale. The first commercial application is expected to be for stroke patients, followed by one for MS patients. There are an estimated 3 million stroke patients with lower limb disability in the US, and approximately 400,000 individuals with multiple sclerosis.

“Our collaboration with ReWalk is a wonderful example of the Wyss Institute model in action,” said Wyss Institute founding director Don Ingber. “We work with industry to help de-risk the technologies we develop, both technically and commercially, and thereby expedite their translation into real world applications.”

“Harvard and its Wyss Institute are pioneers in the development of technology in this space,” said Jasinski. “The licensed Harvard patent portfolio currently includes 19 patent applications, which includes applications in at least six countries. The applications cover the soft suit, control systems and methods of treating patients. Harvard and the Wyss Institute have built comprehensive research expertise in addition to the worldwide patent portfolio. There is no better partner than these renowned institutions with which to pursue the mission of bringing cutting-edge technology to disabled individuals around the world.”

Join us!
A message from the Editor of Times of Israel
David Horovitz

The Times of Israel covers one of the most complicated, and contentious, parts of the world. Determined to keep readers fully informed and enable them to form and flesh out their own opinions, The Times of Israel has gradually established itself as the leading source of independent and fair-minded journalism on Israel, the region and the Jewish world.

We've achieved this by investing ever-greater resources in our journalism while keeping all of the content on our site free.

Unlike many other news sites, we have not put up a paywall. But we would like to invite readers who can afford to do so, and for whom The Times of Israel has become important, to help support our journalism by joining The Times of Israel Community. Join now and for as little as $6 a month you can both help ensure our ongoing investment in quality journalism, and enjoy special status and benefits as a Times of Israel Community member.

Become a member of The Times of Israel Community
read more: